BIIB Form 4: Director Jesus B. Mantas Gets 2,370-Share Stock Grant

Rhea-AI Filing Summary

Biogen Inc. (BIIB) – Form 4 insider filing

Director Jesus B. Mantas reported one transaction dated 06/17/2025. The filing shows an "A" transaction code (acquisition) for 2,370 shares of Biogen common stock at a stated price of $0.00, indicating a stock award or grant. After this transaction, the director’s direct beneficial ownership increases to 9,758 shares. No derivative security transactions were reported, and there are no sales or dispositions disclosed in the filing.

The form was signed by an attorney-in-fact on 06/18/2025. No other insiders or joint filers are involved, and there is no indication that the reporting person is no longer subject to Section 16.

Positive

• Insider acquisition: Director Jesus B. Mantas acquired 2,370 BIIB shares, increasing direct ownership to 9,758 shares.
• No insider sales: The filing contains only acquisitions, signaling continued confidence and alignment.

Negative

• None.

Insights

Securities Analyst

TL;DR: Small insider stock award—positive alignment, limited market impact.

The acquisition of 2,370 BIIB shares for no cash consideration signals routine equity compensation for Director Jesus B. Mantas. Although the dollar value is modest relative to Biogen’s market capitalization, any additional insider ownership marginally aligns board interests with shareholders. No sales were reported, which avoids negative optics. From a trading perspective, the event is unlikely to move the stock, but it adds a slice of constructive sentiment around governance and insider commitment.

Corporate Governance Expert

TL;DR: Routine director grant, governance-neutral, mildly positive for alignment.

Form 4 shows a straightforward equity grant under code "A"—commonly restricted stock—consistent with standard board compensation programs. The post-grant holding of 9,758 shares places the director above the typical minimum ownership guidelines many S&P 500 boards set, supporting best-practice alignment. No dispositions, pledges, or 10b5-1 plan notations were disclosed, reducing potential governance red flags. Overall, the filing is standard but modestly positive for ownership alignment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mantas Jesus B

(Last) (First) (Middle)

BIOGEN INC.

225 BINNEY ST.

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		A		2,370	A	$0	9,758	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Wendell Taylor, Attorney in Fact for Jesus B. Mantas	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Biogen (BIIB) shares did Director Jesus B. Mantas acquire?

2,370 shares were acquired on 06/17/2025.

What was the purchase price for the acquired BIIB shares?

The Form 4 lists a price of $0.00, indicating a stock grant or award.

What is the director’s total BIIB share ownership after the transaction?

Jesus B. Mantas now beneficially owns 9,758 shares directly.

Were any BIIB shares sold in this Form 4 filing?

No. The filing reports no dispositions; only an acquisition is shown.

Does the Form 4 mention any 10b5-1 trading plan?

The form provides a checkbox but does not indicate that the transaction was executed under a 10b5-1 plan.